Current Report Filing (8-k)
December 03 2021 - 6:06AM
Edgar (US Regulatory)
0001662382
false
0001662382
2021-12-01
2021-12-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): December
1, 2021
BRAIN SCIENTIFIC INC.
(Exact name of registrant as specified in its charter)
Nevada
|
|
333-209325
|
|
81-0876714
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
125 Wilbur Place, Suite 170
Bohemia, NY 11716
(Address of Principal Executive Offices)
(917) 388-1578
Registrant’s telephone number, including
area code
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Not applicable
|
|
Not applicable
|
|
Not applicable
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 4.01. Changes in Registrant’s Certifying
Accountant.
(a) Change of Independent registered Public
Accounting Firm
On December 1, 2021, Brain Scientfic Inc. (the
“Company”) changed auditors from Sadler, Gibb & Associates LLC
(“Sadler Gibb”).
Sadler Gibb’s
audit report on the Company's consolidated financial statements as of and for the fiscal years ended December 31, 2020 and 2019 contained
a going concern qualification. During the fiscal years ended December 31, 2020, and 2019, and the subsequent interim period through September
30, 2021, there were (i) no disagreements with Sadler Gibb on any
matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures, which disagreements, if
not resolved to the satisfaction of Sadler Gibb, would have caused Sadler
Gibb to make reference to the subject matter of the disagreement in connection with its reports; (ii) no reportable events as defined
in Item 304(a)(1)(v) of Regulation S-K.
The Company has provided Sadler
Gibb a copy of the disclosures in this Form 8-K and has requested that Sadler
Gibb furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with
the Company’s statements herein. A copy of such letter, which is dated December 1, 2021, is filed as Exhibit 16.1 to this Form 8-K.
(b) New Independent registered Public Accounting
Firm
Effective December 1, 2021, the Company engaged Accell
Audit and Compliance PA (“Accell”) as the Company’s new independent registered public accounting firm. Accell
served as the auditor of Piezo Motion Corp. since 2018. Piezo Motion Corp. merged with the Company as of October 1, 2021. The decision
to engage Accell was approved by the Company’s Board of Directors.
During
the fiscal years ended December 31, 2020, and 2019, and the subsequent interim period through September 30, 2021, neither the Company
nor anyone on its behalf has consulted with Accell regarding (i) the application of accounting principles to any specified transaction,
either completed or proposed; (ii) the type of audit opinion that might be rendered on the Company’s financial statements, and either
a written report was provided to the registrant or oral advice was provided that the new accountant concluded was an important factor
considered by the registrant in reaching a decision as to the accounting, auditing or financial reporting issue; or (iii) any matter that
was either the subject of a disagreement (as defined in Item 304(o)(1)(iv)) or a reportable event (as defined in Item 304(a)(1)(v)).
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BRAIN SCIENTIFIC INC.
|
|
|
|
Dated: December 2, 2021
|
By:
|
/s/ Hassan Kotob
|
|
|
Hassan Kotob
Chief Executive Officer
|
2
Brain Scientific (CE) (USOTC:BRSF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Brain Scientific (CE) (USOTC:BRSF)
Historical Stock Chart
From Jul 2023 to Jul 2024